Ciclesonide for asthma
Canadian Coordinating Office for Health Technology Assessment
Record ID 32004000639
English, French
Authors' objectives:
To summarize the available information on the use of ciclesonide, an inhaled corticosteroid (Trade Mark: Alvesco, manufactured by Altana AG), for the management of asthma in adults and children four years of age and older.
Authors' recommendations:
No studies describing the effect of ciclesonide on clinical outcomes such as exacerbations, hospitalizations, quality of life, and long-term adverse events have been done. Initial data demonstrating a lack of cortisol suppression with two weeks of therapy appear promising; however, longer-term data are necessary, as long-term administration is required for continued control of asthma and allergic rhinitis.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Adrenal Cortex Hormones
- Anti-Asthmatic Agents
- Asthma
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.